Safety of tiagabine: summary of 53 trials

We reviewed the clinical safety of tiagabine HCl (TGB), a selective CNS GAB A uptake inhibitor, in nearly 3100 patients from 53 separate clinical trial s. TGB was found to have no clinically important effect upon hepatic metabo lic processes, serum concentrations of concomitant antiepileptic drugs (AED s), laboratory values, or important interactions with any common non-AEDs. Adverse effects were usually mild and involved the nervous system. TGB is s afe and well-tolerated as add-on therapy for the treatment of partial seizu res. (C) 1999 Elsevier Science B.V. All rights reserved.